GGrantIndex
Sort

48,018 grants matching immunotherapy

Improved therapy for p53wt melanoma by functionally restoring the CDKN2A pathway

$372,875
Ann Richmond · Vanderbilt University · R01 · FY2016 · CA

Improved therapy for p53wt melanoma by functionally restoring the CDKN2A pathway

$372,875
Ann Richmond · Vanderbilt University · R01 · FY2017 · CA

Project 2: Spatial Architecture of Tumor-Mediated Immunosuppression

$372,870
Garry P Nolan · Stanford University · U54 · FY2020 · CA

MAPK as target of glioma immunoediting by CD8 T-cells, and predictor of response to immunotherapy

$372,867
Adam M Sonabend · Northwestern University At Chicago · R01 · FY2021 · NS

Stability and potency of LAP+FOXP3+Tregs as novel cell therapy for GVHD

$372,863
Dat Quoc Tran · University Of Texas Hlth Sci Ctr Houston · R01 · FY2012 · HL

Correlates of antitumor immunity in colorectal cancers and anti PD1 therapy

$372,863
Franck Housseau · Johns Hopkins University · R01 · FY2016 · CA

Imaging T-cell Activation and Co-stimulation in Prostate Cancer Immunotherapy

$372,861
Vladimir Ponomarev · Sloan-Kettering Inst Can Research · R01 · FY2011 · CA

Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients with High-

$372,861
Nai-Kong V Cheung · Sloan-Kettering Inst Can Research · R21 · FY2011 · CA

Human mast cells as a platform for new cancer immunotherapy strategies

$372,846
Chris L Kepley · Liberty University, Inc. · R15 · FY2023 · CA

Tumor cell instrinsic DNA damage signaling to the immune response

$372,839
Roger A Greenberg · University Of Pennsylvania · P01 · FY2025 · CA

HTS for the discovery of activators of NK cell cytotoxicity

$372,835
David Wald · Case Western Reserve University · R01 · FY2023 · CA

Novel ways to prevent upper GT infection

$372,805
Kathleen A. Kelly · University Of California Los Angeles · R01 · FY2014 · AI

Understanding the Mechanism of Mucosal Immunotherapy

$372,751
Arvil Wesley Burks · Univ Of North Carolina Chapel Hill · R01 · FY2014 · AI

Mechanisms and consequences of iNKT cell anergy

$372,695
Luc Van Kaer · Vanderbilt University · R01 · FY2010 · AI

Novel Biological Activities of Anti-Viral Antibody

$372,690
University Of California Irvine · R01 · FY2004 · AI

New Strategies for Treatment of NRAS Mutant Melanoma after Progression on Immune Checkpoint Inhibitors

$372,669
Ann Richmond · Vanderbilt University · R01 · FY2022 · CA

Understanding the Mechanism of Mucosal Immunotherapy

$372,651
Arvil Wesley Burks · Univ Of North Carolina Chapel Hill · R01 · FY2015 · AI

Adenovirus as a Vector for Gene Therapy

$372,644
Patrick Hearing · State University New York Stony Brook · R01 · FY2010 · AI

Monoclonal antibodies to inhibit Aspergillus germination

$372,563
Marta L. Feldmesser · Albert Einstein College Of Medicine · R01 · FY2006 · AI

Role of cross-presentation by APCs in modulating graft-versus-leukemia responses

$372,559
Pavan Reddy · University Of Michigan At Ann Arbor · R01 · FY2008 · HL

Understanding the Mechanism of Mucosal Immunotherapy

$372,549
Arvil Wesley Burks · Univ Of North Carolina Chapel Hill · R01 · FY2016 · AI

Virulence and Immunity to Staphylcocci

$372,549
Brigham And Women'S Hospital · R01 · FY2004 · AI

MicroRNA-15a/16-mediated cytokine/chemokine reprogramming in Kupffer cells prevents the development of hepatocellular carcinoma

$372,485
Guisheng Song · University Of Minnesota · R01 · FY2022 · CA

MicroRNA-15a/16-mediated cytokine/chemokine reprogramming in Kupffer cells prevents the development of hepatocellular carcinoma

$372,485
Guisheng Song · University Of Minnesota · R01 · FY2025 · CA

CELLULAR AND MOLECULAR CHARACTERIZATION OF REGULATORY T CELL DEVELOPMENT

$372,438
Chyi S Hsieh · Washington University · R01 · FY2011 · AI